New rules and guidance must name any approved overdose reversal drug
What the document says“The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act”
The section requires the Secretary to ensure that, in new regulations or guidance for any grant program addressing opioid misuse and use disorders, a reference to an overdose reversal drug such as naloxone covers any approved overdose reversal drug for emergency treatment of a known or suspected opioid overdose.
What the document actually says“The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act”
New rules and advice must not name only one drug. If they name naloxone, they must cover the others too. Any approved reversal drug counts.
Naloxone was the first drug to reverse an opioid overdose. Others have since been approved. Naming only the first can leave the newer ones out.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.